A phase II randomised, double blind, placebo-controlled study of recombinant human relaxin in patients with decompensated congestive heart failure.

Trial Profile

A phase II randomised, double blind, placebo-controlled study of recombinant human relaxin in patients with decompensated congestive heart failure.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors Corthera
  • Most Recent Events

    • 06 May 2014 Status changed from completed to discontinued, as per ClinicalTrials.gov record.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Aug 2007 Status changed from recruuiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top